EGPA patient with chest pain

What were the main findings from the trial and why are they significant? 

MANDARA is the first head-to-head trial of biologics in patients with eosinophilic granulomatosis with polyangiitis (EGPA) and the first to demonstrate that remission is an achievable treatment goal for EGPA patients with eosinophil-targeting biologic therapies.  The MANDARA results also showed that treatment with Fasenra was associated with a greater reduction of blood eosinophil (a type of white blood cell) counts and more patients were able to taper off oral corticosteroids (OCS) versus the current biologic standard.  Recognising the daily challenges faced by the patient communities living with inflammatory disorders like EGPA, pioneering research such as MANDARA aims to redefine patient care. 

What is Fasenra (benralizumab) and why does it have potential for EGPA? 

Fasenra is a monoclonal antibody that binds directly to the IL-5 receptor alpha on eosinophils, attracting natural killer cells to induce rapid and near-complete depletion of blood and tissue eosinophils in most patients via apoptosis (programmed cell death).  There is a high unmet medical need in EGPA as there are limited treatment options and not all patients respond to currently available treatments.

First patients dosed with Fasenra in three dermatology trials